Medicamen Biotech Ltd.
NSE: MEDICAMEQ | BSE: 531146
₹227.80
₹2.55
(1.13%)
As on 16-Jun-2026IST
Market cap
₹309 Cr
Revenue (TTM)
₹198 Cr
P/E Ratio
32
P/B Ratio
1.1
Div. Yield
0.4 %
Quality Score
1/10
Growth Score
5/10
Valuation Score
5/10
Momentum Score
1/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹11 Cr
-
ROE
3.2 %
-
ROCE
5.8 %
-
Industry P/E
57.33
-
EV/EBITDA
14.3
-
Debt to Equity
0
-
Book Value
₹198.2
-
EPS
₹8
-
Face value
10
-
Shares outstanding
13,562,815
10 Years Aggregate
CFO
₹17.13 Cr
EBITDA
₹176.86 Cr
Net Profit
₹98.88 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Medicamen Biotech
| -37.5 | -17.9 | -16.3 | -44.8 | -30.0 | -- | -- |
|
BSE Healthcare
| 8.3 | -0.3 | 9.9 | 6.9 | 23.6 | 13.2 | 12.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Medicamen Biotech
| -27.8 | -13.3 | -27.4 | -6.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Medicamen Biotech
|
227.8 | 308.7 | 197.8 | 9.8 | 6.3 | 3.9 | 32 | 1.1 |
| 1,642.0 | 27,501.8 | 2,762.9 | 509.8 | 22.5 | 21.5 | 54.5 | 11.0 | |
| 778.7 | 31,136.8 | 3,904.6 | 239.4 | 13.3 | 11.1 | 129 | 13.9 | |
| 535.4 | 1,740.2 | 772.8 | 101.5 | 15.7 | 10.7 | 17.2 | 1.8 | |
| 534.2 | 11,070.5 | 1,645.9 | 191.2 | 16.2 | 13.3 | 58.3 | 7.3 | |
| 743.1 | 7,451.3 | 755.8 | 67.1 | -- | 13.8 | 97 | 6.7 | |
| 305.6 | 969.1 | 1,319.3 | -1.5 | -4.5 | 0.3 | 824.1 | 1.5 | |
| 270.1 | 1,403.1 | 310.4 | 31.4 | 17.4 | 13.5 | 43.6 | 5.7 | |
| 533.6 | 8,485.1 | 829.0 | 162.9 | 24.5 | 29 | 51.9 | 14.7 | |
| 1,298.6 | 13,355.5 | 814.2 | 173.0 | 30.1 | 19 | 77.2 | 14.0 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Medicamen Biotech
Medicamen Biotech Limited researches, develops, manufactures, markets, sells, and distributes pharmaceutical formulations and APIs in India. The company offers a range of products, including tablets, such as non-beta lactam tablets; capsules... comprising beta and non-beta lactam capsules; liquid and dry syrups; and ointments and creams. It also provides oral solid and liquid products. The company's products are used in various therapeutic areas, such as gastrointestinal, pain management, anti-infectives, pediatrics, dermatology, gynecology and rheumatology, diabetology, cardiology, oncology, and the central nervous system. Medicamen Biotech Limited was incorporated in 1993 and is based in New Delhi, India. Read more
-
Incorporated
1993
-
Chairman
Rahul Bishnoi
-
Managing Director
--
-
Headquarters
New Delhi, Delhi
-
Website
Looking for more details about Medicamen Biotech Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
FAQs for Medicamen Biotech
What is the current share price of Medicamen Biotech Ltd Today?
The share price of Medicamen Biotech Ltd is ₹227.80 (NSE) and ₹227.60 (BSE) as of 16-Jun-2026 IST. Medicamen Biotech Ltd has given a return of -30.01% in the last 3 years.
What is the current PB & PE ratio of Medicamen Biotech Ltd?
The P/E ratio of Medicamen Biotech Ltd is 32.02 times as on 16-Jun-2026, a 44 discount to its peers’ median range of 57.33 times.
The P/B ratio of Medicamen Biotech Ltd is 1.15 times as on 16-Jun-2026, a 89 discount to its peers’ median range of 10.82 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
93.43
|
2.97
|
|
2024
|
51.31
|
2.43
|
|
2023
|
56.31
|
4.51
|
|
2022
|
52.79
|
5.67
|
|
2021
|
53.78
|
5.17
|
What is the 52 Week High and Low of Medicamen Biotech Ltd?
The 52-week high and low of Medicamen Biotech Ltd are Rs 447.65 and Rs 216.95 as of 16-Jun-2026.
What is the market cap of Medicamen Biotech Ltd?
Medicamen Biotech Ltd has a market capitalisation of ₹ 309 Cr as on 16-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Medicamen Biotech Ltd?
Before investing in Medicamen Biotech Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.